Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Non-cash Items (2023 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Non-cash Items for 3 consecutive years, with $7.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-cash Items fell 32.71% to $7.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $7.2 million, a 32.71% decrease, with the full-year FY2024 number at $3.0 million, down 63.35% from a year prior.
  • Non-cash Items was $7.2 million for Q3 2025 at Orchestra BioMed Holdings, down from $8.3 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $10.7 million in Q3 2024 to a low of $1.4 million in Q1 2024.
  • A 3-year average of $6.0 million and a median of $7.2 million in 2025 define the central range for Non-cash Items.
  • Peak YoY movement for Non-cash Items: crashed 81.42% in 2024, then skyrocketed 388.24% in 2025.
  • Orchestra BioMed Holdings' Non-cash Items stood at $8.2 million in 2023, then plummeted by 63.35% to $3.0 million in 2024, then skyrocketed by 140.0% to $7.2 million in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Non-cash Items are $7.2 million (Q3 2025), $8.3 million (Q2 2025), and $3.7 million (Q1 2025).